NovoCure Limited (NVCR)

Market Cap	1.43B
Revenue (ttm)	642.27M
Net Income (ttm)	-177.65M
Shares Out	111.98M
EPS (ttm)	-1.61
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,235,778
Open	12.81
Previous Close	12.64
Day's Range	12.53 - 12.82
52-Week Range	10.70 - 34.13
Beta	0.83
Analysts	Buy
Price Target	28.64 (+124.28%)
Earnings Date	Oct 30, 2025

About NVCR

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was inc...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Oct 2, 2015
• Employees: 1,488
• Stock Exchange: NASDAQ
• Ticker Symbol: NVCR
• Website: https://www.novocure.com

Financial Performance

In 2024, NovoCure's revenue was $605.22 million, an increase of 18.82% compared to the previous year's $509.34 million. Losses were -$168.63 million, -18.55% less than in 2023.

Analyst Summary

According to 7 analysts, the average rating for NVCR stock is "Buy." The 12-month stock price target is $28.64, which is an increase of 124.28% from the latest price.

Price Target

$28.64

(124.28% upside)

Analyst Consensus: Buy